Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Lymphoid 6Other hematologic neoplasm 4Gynecologic 4Gastrointestinal 4Breast 4Sarcoma 3Genitourinary 3Dermatologic 3Head & Neck 2Classical hematology 2Plasma cell 1Myeloid 1CNS 1

Conditions

Anemia, Refractory, with Excess of Blasts 115Myelodysplastic Syndromes 107Leukemia 98Leukemia, Myeloid, Acute 92Anemia 70Leukemia, Myelomonocytic, Chronic 68Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Myeloproliferative Disorders 55Leukemia, Lymphocytic, Chronic, B-Cell 52Multiple Myeloma 48Anemia, Refractory 48Thrombocytopenia 45Lymphoma 43Lymphoma, Non-Hodgkin 42Neoplasms 40Hodgkin Disease 39Primary Myelofibrosis 36Leukemia, Myeloid, Chronic-Phase 36Congenital Abnormalities 34Anemia, Aplastic 34Myelodysplastic-Myeloproliferative Diseases 33Leukemia, Myelogenous, Chronic, BCR-ABL Positive 33Leukemia, Myeloid, Accelerated Phase 32Lymphoma, Follicular 29Blast Crisis 27Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 26Burkitt Lymphoma 25Lymphoma, Mantle-Cell 24Neoplasms, Plasma Cell 23Lymphoma, B-Cell, Marginal Zone 23

Interventions

pegfilgrastim 2sodium thiosulfate 1etoposide phosphate 1Rituximab 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Docetaxel 1Darbepoetin alfa 1Cytarabine 1Cyclophosphamide 1Cisplatin 1Carboplatin 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Drug-Related Side Effects and Adverse Reactions × Classical hematology × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT00077311 2016-06-30

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
160 enrolled
Classical hematologyThoracic

Adenocarcinoma of Lung, Anemia, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutropenia, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡